Edison Pharmaceuticals

Edison Pharmaceuticals is a biotechnology company focused on developing innovative therapies for various diseases, leveraging its expertise in pharmacology and drug development to address unmet medical needs. Founded in 2005 in Mountain View, US, Edison Pharmaceuticals specializes in the development of therapies for rare diseases. The company raised USD 50 mn in Series G funding from Dainippon Sumitomo and others on March 27, 2014, bringing its total amount raised to USD 50 mn, with a current valuation of USD 1,389. 70 mn.

Edison Pharmaceuticals is primarily engaged in the development of pharmaceutical products aimed at treating rare diseases. The company's pipeline includes several investigational drugs designed to target specific conditions, ensuring they meet the needs of patients with limited treatment options. Edison Pharmaceuticals generates revenue through its pharmaceutical developments, which may include licensing agreements and partnerships with larger pharmaceutical companies as they advance their product pipeline. Details on specific revenue figures are not disclosed.

Edison Pharmaceuticals aims to leverage its recent Series G funding of USD 50 mn to accelerate the development of its pipeline products. The company plans to expand its research initiatives and explore opportunities in new geographic markets, particularly targeting Europe and Asia by 2025. This strategic growth will support their mission to deliver innovative therapies to patients worldwide.